ReviewFrontiers in immunology2026
Viral encephalitis related to adalimumab in a 16-year-old Crohn's disease patient: case report and literature review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor-alpha (TNF-α) inhibitors are extensively utilized in inflammatory bowel disease (IBD). Adalimumab (ADA), a TNF-α inhibitor, appears to be an effective and safe option for pediatric Crohn's disease (CD), but the potential risk of opportunistic infection and autoimmune disease is of particular concern. We present the first pediatric case of viral encephalitis (VE) in a 16-year-old boy with CD following treatment with ADA. A 16-year-old CD patient developed symptoms such as fever, dizziness, drowsiness, and blurred vision after three months of ADA treatment. Fundoscopic examination demonstrated pronounced edema of the optic disc in both eyes. The lumbar puncture revealed a marked elevation in intracranial pressure and pathogen analysis of the cerebrospinal fluid identified an HHV-7 infection using next generation sequencing. Following discontinuation of ADA and treatment with acyclovir, the child's symptoms largely subsided. Literature search identified 11 published CD adult patients with neurological complications related to ADA treatment, while 7 cases were diagnosed with autoimmune encephalitis and 4 with Guillain-Barré syndrome. This report presents the first pediatric CD patient with treatment of ADA, during which VE manifested. Although neurological adverse events associated with ADA are infrequent in pediatrics, vigilant monitoring for neurological symptoms, particularly for infections, remains critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.